午夜一级毛片-手机看片99-动漫人物桶机免费动漫app-日日摸日日碰夜夜97|www.zyjlr.com

TEL:020-31701980      FAX:020-31701979     E-mail:sales@mx008.com
China Mingxuan
Service Hotline:020-3171980
搜索

News
MX trends
industry trends
fair information
 
Micro-channel
 
Information details You are here:Home >> News >> industry trends
 
《Development planning guide》Let the hospitals and drug companies will be closer together
 
Author:中國銘鉉 企劃部  Release Time:2016-11-11 12:00:54  Number Browse:1193
 

Medical network - on November 10, on November 7, 2016 by the ministry of industry, the national development and reform commission, ministry of science and technology, ministry of commerce, the national health and family planning commission, the state food and drug supervision and administration bureau, six ministries jointly issued "the pharmaceutical industry development planning guide" (hereinafter referred to as the "guidelines") jointly issued officially.

The guide from enhance the industry innovation ability, improve the level of quality and safety, improving the capacity of supply security, promote green upgrade, promote two depth fusion, optimize the industrial organization structure, improve the level of internationalization development, develop new areas of development new formats and so on eight aspects proposed the concrete task deployment.

As "much starker choices-and graver consequences-in" to guide the development of the pharmaceutical industry special planning guide, the guide is made clear the deficiency existing in the present our country medicine industry with difficulty, also indicate the necessity for the pharmaceutical industry from large to strong, for the future development of Chinese pharmaceutical industry, there is no doubt that the vane of explanatory significance. The word long, these key points worth attention.

A, the relationship between medical institutions and pharmaceutical industry will be more closely

In the future, industry innovation will become the key words of pharmaceutical industry in our country, and to realize "zheng production, with" the integration of collaborative innovation system, cannot leave the technical collaboration of medical institutions. The guide pointed out that to promote medical institutions, colleges and universities, research institutes and other organizations, and the technical coordination of the enterprise, establishment conforms to the characteristics of the new drug research and development investment, income, risk sharing mechanism, accelerate the industrialization of research results.

Medical institutions is an indispensable part in the process of new drug research and development, but in the present medical industry environment, between medical institutions and pharmaceutical companies shows a tendency of "not enough". Especially the ongoing quality of generic drugs and curative effect evaluation, consistency, the shortage of the clinical trial base of resources has become the pharmaceutical companies to carry out the consistency evaluation of important factor. The guide clear should arouse the enthusiasm of medical institutions in medical innovation, improve the level of new drug clinical research, promote the transformation of scientific and technological achievements and application.

Drug and medical device clinical trial base (GCP) base construction and management will be further specification, thus building up before clinical efficacy evaluation platform, to strengthen the research and development support. Pharmaceutical research and development of public data and resources platform construction will be strengthened, so as to improve the level of open sharing and professional service ability.

Second, the construction of the medicine industry venture capital fund of 10 billion yuan of above

Guide social capital to set up venture capital funds, equity funds, in medical industry will become an important factor in the development of the pharmaceutical industry to support the future. According to the guidelines published by the pharmaceutical industry venture capital plan, future will guide social capital to set up more than 50 medicine industry venture capital fund, the total scale of 10 billion yuan of above, to provide financing support for medical technology innovation projects, to help early r&d project implementation and innovative enterprise growth.

Simultaneously small micro enterprise innovation innovation service platform construction, support the construction of business incubators, opening laboratory, science and technology achievements transformation center innovation innovation service platform.

The construction of the medicine industry venture capital fund also will continue to implement "major drug discovery" is a national science and technology major projects such as national important foundation of industrialization of science and technology plan and special medicine and the development of venture investment funds and equity funds, will help to broaden the financing channels, reduce the cost of financing, so as to promote the innovation product research and development and large-scale application.

Third, development of traditional Chinese medicine will be more valued

An undeniable fact is that, although the national policy has encouraged the development of traditional Chinese medicine, but on the road of the Renaissance still face many dangers such as Chinese herbal medicine planting the prohibition is not standard, counterfeiting adulteration phenomenon. But maybe there will be a change in the future.

The guide is put forward to improve Chinese traditional medicine quality standard system, enhance the level of the whole traditional Chinese medicine industry chain quality control, improve product quality homogeneity and controllability, this undoubtedly for medicines and proprietary Chinese medicine quality standard and quality more strict requirements are put forward.

And application of traditional Chinese medicine in clinical and pharmaceutical industry will be more valued. For advantages of traditional Chinese medicine disease to develop compound active ingredients, effective parts and traditional Chinese medicine research focus on variety, quality is stable and controllable, outstanding clinical advantages of modern traditional Chinese medicine (TCM). Protection and inheritance of traditional Chinese medicine brand at the same time, promote the quality and safety level improvement and industrial upgrading.

The guide has made the traditional Chinese medicine quality improvement plan. Implement the development projects of rejuvenating Chinese medicine, Chinese medicine yinpian support, traditional Chinese medicine (TCM) of essential medicines, traditional Chinese medicine injections, focus on product quality improvement; To develop and promote large varieties of traditional Chinese medicine production quality control standards and product standards, construction of the whole process of Chinese medicinal materials traceability system. At the same time to carry out national census of resource of traditional Chinese medicine (TCM), the establishment of traditional Chinese medicine resources dynamic monitoring and technical service network, established germplasm resources protection system of Chinese medicine, medicinal germplasm resources and biodiversity protection, guide the enterprise standardization construction of Chinese herbal medicine planting breeding base.

Four, drug supply will has been further guaranteed

For a long time, some medicine for clinical medicine, cheap foreclosures news we see an endless, as the market is small space, low profit margins, leading to production enterprise motivation is not strong. And although the country is adopted such as fixed-point production incentives, but the effect is still weak. As a result, the guide will promote drug supply security ability also made special.

The guide pointed out that to guarantee drug supply shortage, it should strengthen the drug monitoring the supply and demand information, set up drug shortage of early warning system, the integrated use of regulation, health care, price, purchase, use, such as policies, guide the enterprises to develop and produce a shortage of medicine, support the construction of concentrated production base of small drug varieties, dosage of continuing small, clinical necessary, market supply drugs designated production pilot.

Even at the same time improve the national pharmaceutical reserve system. Revised "national medicine reserves management method", give full play to the national pharmaceutical reserve function, raise reserve resources use efficiency. On the basis of the emergency safeguard, establish normal drugs reserves, implement the central and the local medical reserve connectivity information system, information monitoring and data inquiry, online reserves stockpile orders, varieties of real-time scheduling, improve emergency response capabilities.

In addition, to strengthen the construction of the emergency medicine research and development and industrialization base for new hair abrupt infectious diseases, as well as other endanger the safety of national public health emergency needs, relying on conditional enterprises and research institutions, construction of civil-military integration of medicines, vaccines, rapid development and production base, can satisfy the needs for disease control and prevention.

5, Internet + medicine was the development of new formats

Seeking medical treatment as the "160", "sought treatment network, mobile Internet companies such as the bad news, have showed that 2016 mobile medical speech has entered the winter period, capital blowing bubble has burst, but in the" guide ", "Internet + medicine", including mobile medical treatment, the push will still be the main direction, such as the development and application function of cloud services and artificial intelligence mobile medical products, wearable equipment, various types of health management based on mobile Internet software (APP), which can realize remote monitoring and consulting of remote medical system.

The guide, to strengthen the development and utilization of health care big data, the development of electronic health records, electronic medical records, electronic prescription, such as database, realizing the connectivity and sharing of data resources, guide the diagnosis and treatment of disease, drug evaluation and new drug development, the development of medical decision support system based on big data. Foster new health consumer demand at the same time, drive home, provide for the aged, rehabilitation medical equipment development and application, to meet the need of the aging of the population. The development of health products.

The guide also encourage pharmaceutical enterprises to functional foods, special medical use formula food, cosmetics and health care, prevention, not cure disease, and other fields. Especially the gene sequencing, emerging medical technology such as tumor immunotherapy, stem cell therapy will be supported.

Six, drug prices, procurement and health policy to further improve

With comprehensively deepen the reform of medical health system, and the grading system to speed up the reform of public hospitals, market leading drug price formation mechanism is gradually established, with the "double envelope system, directly net, price negotiation, fixed-point production of drug classification procurement policy, the full implementation of the medicare payment standard gradually establish, health charged fees and medical institutions comprehensive control measures, the pharmaceutical industry development trend and competition will have a profound impact.

One of the most practical significance of measures to curb drug prices artificially high, this will require a price policy and healthcare, procurement, etc. To achieve good cohesion, can inhibit drug prices artificially high at the same time, avoid low prices impact supply to ensure the safety and quality. Improve drug classification procurement policies, science set up the public bidding evaluation standard, improve the method of quality evaluation, promoting evolution.

In matters of health insurance directory according to the medical insurance fund bear ability, will conform to the conditions of innovation medicine into the medical insurance directory by the regulation, scientific and rational formulation adjustment medicine of insurance of primary medical treatment to pay standard, payment to promote health care reform. Vigorously develop commercial health insurance at the same time, meet the demand of diversified and multi-level health security.

Seven, the medicine circulation system will be further improved

As the "two votes" and the advancement of "votes" drugs circulation become one of the hottest keywords in the pharmaceutical industry. Two votes a will to a large extent, makes the traditional circulation "ticket" in the "ticket" and other illegal links contained, purifying the circulation environment. Also put forward, the guide will further strengthen the drug circulation network construction, formed closely with industrial enterprises and circulation enterprises at all levels, the national channels and regional coordination of drug distribution network.

At the same time, the development of third-party medical logistics. Some traditional logistics enterprises in the field of such as motion are also entering the medical logistics market, its powerful terminal cover ability and perfect logistics channels will help the complete finishing in the field of pharmaceutical logistics, ensure correct delivery of the last kilometer, realize effective covering of medicine circulation to the grassroots.

The guide also points out that to guide the medicine circulation enterprises to develop modern medicine logistics, using information technology to implement supply chain management, integration of upstream and downstream resources, makes the whole industry chain service mode, improve the efficiency of the whole supply chain.

 
Previous article:My state: this article 24 the official to the country to promote health care reform experience
Next article:Medical equipment three big multinational companies calculate SBC to import substitution
 
Log in  Website Map All right reserved by China Mingxuan, Guangzhou ICP #16026227
    

粵公網安備 44011202000029號